XTX Topco Ltd Invests $1.39 Million in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

XTX Topco Ltd acquired a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,220 shares of the biopharmaceutical company’s stock, valued at approximately $1,385,000.

Other large investors also recently added to or reduced their stakes in the company. Oak Ridge Investments LLC purchased a new stake in shares of Intra-Cellular Therapies in the second quarter valued at about $811,000. Perceptive Advisors LLC purchased a new stake in shares of Intra-Cellular Therapies in the 4th quarter valued at approximately $7,735,000. SG Americas Securities LLC increased its holdings in shares of Intra-Cellular Therapies by 962.7% during the 2nd quarter. SG Americas Securities LLC now owns 48,778 shares of the biopharmaceutical company’s stock worth $3,341,000 after buying an additional 44,188 shares during the last quarter. Schroder Investment Management Group raised its position in shares of Intra-Cellular Therapies by 36.7% during the 4th quarter. Schroder Investment Management Group now owns 779,823 shares of the biopharmaceutical company’s stock valued at $55,851,000 after buying an additional 209,331 shares during the period. Finally, Clearbridge Investments LLC lifted its holdings in Intra-Cellular Therapies by 12.3% in the first quarter. Clearbridge Investments LLC now owns 1,744,551 shares of the biopharmaceutical company’s stock valued at $120,723,000 after acquiring an additional 191,416 shares during the last quarter. 92.33% of the stock is currently owned by hedge funds and other institutional investors.

Intra-Cellular Therapies Stock Up 0.8 %

Intra-Cellular Therapies stock opened at $77.61 on Friday. The company’s 50 day moving average is $75.67 and its two-hundred day moving average is $71.44. The firm has a market cap of $8.19 billion, a PE ratio of -66.91 and a beta of 1.00. Intra-Cellular Therapies, Inc. has a 52-week low of $45.50 and a 52-week high of $84.89.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.03. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The business had revenue of $161.40 million for the quarter, compared to analysts’ expectations of $157.74 million. During the same period last year, the firm earned ($0.45) earnings per share. The company’s revenue for the quarter was up 45.7% compared to the same quarter last year. On average, equities research analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.59 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Sharon Mates sold 53,013 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $80,970,388.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Sharon Mates sold 53,013 shares of Intra-Cellular Therapies stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at approximately $80,970,388.85. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Mark Neumann sold 18,714 shares of the business’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the transaction, the executive vice president now owns 29,700 shares of the company’s stock, valued at approximately $2,229,876. The disclosure for this sale can be found here. In the last quarter, insiders sold 179,778 shares of company stock worth $13,374,538. 3.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Royal Bank of Canada reduced their target price on Intra-Cellular Therapies from $107.00 to $106.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. JPMorgan Chase & Co. boosted their price objective on shares of Intra-Cellular Therapies from $79.00 to $81.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Piper Sandler raised shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $68.00 to $92.00 in a research note on Friday, September 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price target on shares of Intra-Cellular Therapies in a research note on Monday, September 16th. Finally, UBS Group lowered their price objective on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $96.58.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.